Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kane

Showing results (411-420 of 1,451) with videos related to

Pageof 146
Sort By:
The Journal of Clinical Psychiatry|July 12, 2013
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?Jimmi Nielsen, Christoph U Correll, Peter Manu, et al.
Journal of the Neurological Sciences|February 15, 2018
Clinical risk factors for the development of tardive dyskinesiaMarco Solmi, Giorgio Pigato, John M Kane, et al.
Neuroimage|February 5, 2008
Parietal activation during retrieval of abstract and concrete auditory informationEllen C Klostermann, Ari J M Kane, Arthur P Shimamura
Drug Design, Development and Therapy|May 26, 2018
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trialsMarco Solmi, Giorgio Pigato, John M Kane, et al.
Eukaryotic Cell|February 14, 2012
Regulation of vacuolar H+-ATPase activity by the Cdc42 effector Ste20 in Saccharomyces cerevisiaeMeng Lin, Sheena Claire Li, Patricia M Kane, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|April 24, 2019
The Fragility of Statistically Significant Findings in Pediatric Critical Care Randomized Controlled TrialsTravis J Matics, Nadia Khan, Priti Jani, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 8, 2018
Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysisMaren Carbon, John M Kane, Stefan Leucht, et al.
The Journal of Biological Chemistry|July 11, 1998
Characterization of a temperature-sensitive yeast vacuolar ATPase mutant with defects in actin distribution and bud morphologyJ W Zhang, K J Parra, J Liu, et al.
Schizophrenia Research|March 31, 2007
Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disordersLars Helldin, John M Kane, Ulla Karilampi, et al.
Bipolar Disorders|November 27, 2008
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychoticsChristoph U Correll, Anne M Frederickson, John M Kane, et al.
Pageof 146

Showing results (411-420 of 1,451) with videos related to

Sort By:
Pageof 146
The Journal of Clinical Psychiatry|July 12, 2013
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?Jimmi Nielsen, Christoph U Correll, Peter Manu, et al.
Journal of the Neurological Sciences|February 15, 2018
Clinical risk factors for the development of tardive dyskinesiaMarco Solmi, Giorgio Pigato, John M Kane, et al.
Neuroimage|February 5, 2008
Parietal activation during retrieval of abstract and concrete auditory informationEllen C Klostermann, Ari J M Kane, Arthur P Shimamura
Drug Design, Development and Therapy|May 26, 2018
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trialsMarco Solmi, Giorgio Pigato, John M Kane, et al.
Eukaryotic Cell|February 14, 2012
Regulation of vacuolar H+-ATPase activity by the Cdc42 effector Ste20 in Saccharomyces cerevisiaeMeng Lin, Sheena Claire Li, Patricia M Kane, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|April 24, 2019
The Fragility of Statistically Significant Findings in Pediatric Critical Care Randomized Controlled TrialsTravis J Matics, Nadia Khan, Priti Jani, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 8, 2018
Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysisMaren Carbon, John M Kane, Stefan Leucht, et al.
The Journal of Biological Chemistry|July 11, 1998
Characterization of a temperature-sensitive yeast vacuolar ATPase mutant with defects in actin distribution and bud morphologyJ W Zhang, K J Parra, J Liu, et al.
Schizophrenia Research|March 31, 2007
Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disordersLars Helldin, John M Kane, Ulla Karilampi, et al.
Bipolar Disorders|November 27, 2008
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychoticsChristoph U Correll, Anne M Frederickson, John M Kane, et al.
Pageof 146